Siponimod Fumarate is the fumarate salt form of siponimod, an orally bioavailable sphingosine 1-phosphate (S1P) receptor modulator, with potential anti-inflammatory and immunomodulating activities. Upon oral administration, siponimod targets and binds to S1P receptors 1 and 5 on lymphocytes. This prevents the egress of lymphocytes from lymph nodes, thereby reducing both the number of circulating peripheral lymphocytes and the infiltration of lymphocytes into target tissues, including the central nervous system (CNS). This prevents lymphocyte-mediated immune response and may reduce inflammation. S1P plays a key role in lymphocyte migration from lymphoid tissues. Siponimod does not target S1P receptor 3, the activation of which may be responsible for adverse effects including bradycardia associated with other S1P receptor modulators. Its therapeutic use is listed as multiple sclerosis agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Siponimod hemifumaric acid and Siponimod hemifumarate. Its PubChem CID is 46700777.
Siponimod fumarate
| CAS No | 1234627-85-0 |
|---|---|
| Molecular Formula | C62H74F6N4O10 |
| Molecular Weight | 1149.3 g/mol |
| Synonyms | (E)-but-2-enedioic acid;1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Siponimod Fumarate is the fumarate salt form of siponimod, an orally bioavailable sphingosine 1-phosphate (S1P) receptor modulator, with potential anti-inflammatory and immunomodulating activities.
The listed CAS number is 1234627-85-0.
The listed molecular formula is C62H74F6N4O10.
The listed molecular weight is 1149.3 g/mol.
(E)-but-2-enedioic acid;1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid.
The source lists Siponimod hemifumaric acid and Siponimod hemifumarate.